Background {#Sec1}
==========

*Burkholderia pseudomallei* is a gram-negative environmental bacterium found in soil and surface water that causes melioidosis, which most commonly occurs in south-east Asia and northern Australia \[[@CR1]\]. Melioidosis has been increasingly recognised to occur in diverse tropical locations globally, including the Americas and Africa \[[@CR2]\]. *B. pseudomallei* is now classified by the US CDC as a tier-1 select agent because of its aerosolized biothreat potential (<http://www.selectagents.gov/>). Infection can occur through inhalation, aspiration and ingestion, although transmission most commonly occurs via percutaneous inoculation \[[@CR3]\]. Pneumonia is the most common clinical manifestation (presumably via haematogenous spread to the lungs), with a spectrum including mild self-limiting infection, subacute pulmonary disease mimicking tuberculosis, rapidly progressive multifocal pneumonia and systemic sepsis which confers a high mortality of over 50 % \[[@CR4]\]. Melioidosis is often reported in people returning to their home country after travelling to an endemic region. At-risk tourists include those with diabetes and cystic fibrosis (CF) exposed to soil and surface water or monsoonal storms where aerosolization of *B. pseudomallei* may occur \[[@CR1], [@CR2]\].

Generally patients who survive infection clear the organism and rarely relapse following an adequate duration of therapy \[[@CR5]\]. In the 25-year Darwin Prospective Melioidosis Study \[[@CR6]\], only one of over 750 consecutive melioidosis patients had evidence of long-term persisting infection with *B. pseudomallei*. This patient with non-CF bronchiectasis has continued to have positive sputum culture results for *B. pseudomallei* 14 years after diagnosis and treatment of melioidosis. Whole genome sequencing of isolates obtained from this patient over a 12-year period demonstrates loss of virulence and immunogenic factors, as well as deletion of pathways involved in environmental survival \[[@CR7]\]. There have been a number of published case reports of patients with CF who have acquired *B. pseudomallei* infection and a number of these cases have demonstrated chronic carriage of *B. pseudomallei* in patients with CF \[[@CR8]--[@CR17]\].

In this study, we aimed to describe the international experience of infection with *B. pseudomallei* in patients with CF. We have examined potential risk factors for acquisition and persistence of infection, summarised global experience of effective antibiotic strategies, and assessed the long-term clinical sequelae of infection.

Methods {#Sec2}
=======

The study was conducted in accordance with the amended Declaration of Helsinki, and was approved by the local human research ethics committee. (Metro North Hospital and Health Service Human Research Ethics Committee, Queensland, HREC/13/QPCH/51). A literature search (utilising Medline, Embase, CINAHL, AustHealth and ScienceDirect databases and by Google Scholar) was performed to identify all published cases of *B. pseudomallei* infection in patients with CF in July 2013 and repeated in August 2014 (Additional file [1](#MOESM1){ref-type="media"}). Case reports were hand-searched and clinicians from European, North American, and Australasian CF centres that had either reported *B. pseudomallei* in CF patients, or were experts from CF microbiology laboratories, were contacted to locate additional cases not previously reported. Data entry sheets were provided to the clinicians that had supervised the care of the identified cases, and results including contemporaneous clinical metrics were compiled (Additional file [2](#MOESM2){ref-type="media"}). Where supervising clinicians could not be contacted, information was extracted from the published reports \[[@CR8], [@CR9], [@CR11], [@CR14]\]. Chronic infection was defined as persistent cultures of *B. pseudomallei* from sputa or endobronchial washings for 12 months or more.

Results {#Sec3}
=======

Case identification {#Sec4}
-------------------

Twenty-five culture-proven cases between 1987 and 2015 were identified (Table [1](#Tab1){ref-type="table"}). 16 cases were identified by literature search. A further nine cases were identified through international consultation with experts of CF and infectious disease that had experience in the diagnosis and management of *B. pseudomallei* infection. Of the 25 cases, detailed clinical data were made available by the treating clinicians for 21 cases, and in the remaining four cases details were extracted from published reports. An additional two cases were identified where melioidosis was suspected based on positive *B. pseudomallei* serology, although culture confirmation was elusive. Both cases died from progressive refractory respiratory infection after being presumptively infected while travelling overseas; these cases were not included further in this analysis. Three additional possible cases from Mexico were identified through hand-searching references of published articles \[[@CR18]\]. There were insufficient data available and the accuracy of bacterial identification was uncertain, therefore these cases were also excluded.Table 1Cases of culture confirmed B. pseudomallei infection in CFPatientYear isolatedLocation of acquisitionCountry of residenceAgeGenderCFTR MutationFEV~1~%BMICo-pathogensETOH \>40 g dailyDiabetes1 (O'Carroll, 2003) \[[@CR12]\]1987Northern AustraliaAustralia21MF508del/F508del4921PseudNoNo2Early 1990'sNorthern AustraliaAustralia40MF508del/R11744.523PseudYesNo*Mycobacterium intracellulare*3 (Schülin, 2001) \[[@CR14]\]1992Likely ThailandGermany31MUnknownUnknownUnknownUnknownUnknownUnknown4 (Visca, 2001) \[[@CR15]\]1998South-East AsiaItaly25FUnknownUnknownUnknownPseudUnknownUnknownBCp5 (Dance, 1999) \[[@CR11]\]1998MalaysiaEngland20MUnknownUnknownUnknownUnknownUnknownUnknown6 (Holland, 2002) \[[@CR16]\]1999Northern AustraliaNew Zealand8.5MG551D/1717-16 \> A4615PseudNoNo*Aspergillus fumigatus*7 (Holland, 2002) \[[@CR16]\]2000Northern AustraliaNew Zealand7FG551D/1717-16 \> AUnknown19*Haemophilus influenzae*NoNoStaph A8 (O'Carroll, 2003) \[[@CR12]\]2000Northern AustraliaAustralia21MF508del/F508del3522PseudNoYesStaph ABCp9^a^ (Holland, 2002) \[[@CR16]\]2000Northern AustraliaAustralia18MF508del/F508del4521PseudYesNoStaph ABGl*Mycobacterium intracellulare*Other10 (O'Carroll, 2003) \[[@CR12]\]2001Northern AustraliaAustralia14MF508del/G542X8017PseudNoNoStaph11 (Holland, 2002) \[[@CR16]\]2001Northern AustraliaNew Zealand38MF508del/F508del3619PseudNoIFGStaph A12 (O'Carroll, 2003) \[[@CR12]\]2001Northern AustraliaAustralia25FUnknown8020PseudNoNoStaph ABCp13 (Asiah, 2006) \[[@CR8]\]2004MalaysiaMalaysia17MUnknownUnknownUnknownPseudUnknownUnknownStaph A14 (Barth, 2007) \[[@CR9]\]2005BrazilBrazil17FUnknownUnknownUnknownPseudUnknownUnknownStaph A152005ThailandEngland30FUnknown5621PseudNoYesStaph A*Aspergillus fumigatus*16 (Corral, 2008) \[[@CR10]\]2006British Virgin IslandsEngland17MF508del/E60X6322PseudUnknownNoStaph ACanada172007Northern AustraliaAustralia38MF508del/F711 + 5G \> A2919PseudNoNoStaph A*Aspergillus terreus*182007ThailandNew Zealand10FF508del/17aa + IG7410716PseudNoNoStaph AOther192008ThailandAustralia22FF508del/F508del8523PseudYesYes20 (O'Sullivan, 2011) \[[@CR13]\]2009ArubaUSA7FF508del/F508del8813NoneNoNo212010Vietnam/CambodiaEngland23FF508del/F508del4419PseudNoNo*Haemophilus influenzae*22 (Radhakrishna, 2014) \[[@CR17]\]2011ThailandAustralia25MUnknown9524PseudUnknownNo*Aspergillus fumigatus*232012Malaysia/PhilippinesMalaysia19MR553X/unknown1817PseudNoNo242013Thailand/JapanEngland30MF508del/E60X6723PseudNoNo252015ThailandEngland21FF508del/F508del7118PseudNoNoStaph A*Pseud Pseudomona aeruginosa, Staph A Staphylococcus aureus, BCp Burkholderia cepacia* complex, *BGl Burkholderia gladioli, IFG* impaired fasting glucos^a^3 distinct *B. pseudomallei* infections were recorded in this patient over 8 years

Epidemiology and risk factors for *B. Pseudomallei* acquisition {#Sec5}
---------------------------------------------------------------

Of the 25 cases, 15 (62.5 %) were males, and ten females. The median age at acquisition was 21 years (range 7--38 years). The presumptive location of acquisition for the majority was either northern Australia or South-east Asia. There was one case each of presumed acquisition in Brazil, Aruba and the British Virgin Islands, respectively. The mean forced expiratory volume in 1 s (FEV~1~) was 60 % predicted (range 38-107 %) and mean body mass index (BMI) was 19.5 kg/m^2^ (range 13--24). Two cases were siblings. Specific Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) mutations were documented in 17 of the 25 patients. Of these, 47 % (8) were F508del homozygotes and 35 % (6) were F508del heterozygotes. Having CF (pulmonary disease) was the apparent major risk factor in all patients. Of the 19 patients where data were available, CF-related diabetes was present in three (16 %) and there was impaired glucose tolerance in one. Other common risk factors for infection with *B. pseudomallei* such as hazardous alcohol use, chronic renal disease, congestive cardiac failure, rheumatic heart disease and immunosuppressive therapy were not reported in any of the cases.

Clinical and radiological manifestations of infection with *B. Pseudomallei* {#Sec6}
----------------------------------------------------------------------------

Of the 25 patients, clinical manifestations at the presumed time of acquisition were available in 24. In ten (42 %), isolation of *B. pseudomallei* was an incidental finding on routine sputum surveillance and in the remaining 14 patients (61 %), isolation of *B. pseudomallei* was associated with symptoms of increased cough and sputum. Systemic features (either one or a combination of the following: fever, weight loss or deteriorating glycemic control) were reported in 10 patients. New radiological changes were documented in eight patients, with patchy areas of consolidation being the most common abnormality reported. Lobar consolidation, progressive lobar destruction, increased bronchiolectasis with "tree-in-bud" opacities and progressive bronchiectasis were also reported.

Long-term outcomes following infection with *B. Pseudomallei* {#Sec7}
-------------------------------------------------------------

In five patients, acquisition of *B. pseudomallei* did not result in chronic infection (≥12 months). In one of these patients (patient 9), there were three different *B. pseudomallei* infections over an eight-year period, each with distinct organisms as confirmed by multilocus sequence typing, \[[@CR6]\] and each episode was successfully cleared with 2 to 3 week courses of intravenous ceftazidime and oral trimethoprim/sulfamethoxazole (TMP/SMX) followed by consolidation with three months of oral TMP/SMX. This case was considered to have been infected with distinct *B. pseudomallei* strains on three occasions \[[@CR6]\]. Two patients presented with acute pneumonia and the organism was eradicated after a combination of intravenous followed by consolidation nebulized and oral antibiotics (patient 16 and 20). One further patient who was not unwell at the time of isolation of the organism spontaneously cleared the infection without specific antibiotics directed at *B. pseudomallei* (patient 19).

In 19 patients (79 %)*,* initial infection was followed by evidence of chronic infection (range 1 -- 11 years) (Table [2](#Tab2){ref-type="table"}). Of these patients, 14 were thought to have had an accelerated decline in pulmonary status by their physician, although in one case the reported decline occurred after a four-year period of clinical stability despite evidence of persistent infection. Markers of clinical deterioration that were reported included increased exacerbation frequency, reduced response to intravenous antibiotics and an accelerated decline in lung function. Six patients had died by August 2014, between two and six years after the first isolation of *B. pseudomallei* (patients 6, 7, 8, 11, 15 and 18). In two, septicemia was documented and complicated by respiratory failure and death (patients 7 and 15). In one recurrent bacteraemia occurred and oral corticosteroids appeared to precipitate an episode (patient 15). Tigecycline controlled bacteremia despite progressive resistance to TMP/SMX and ceftazidime.Table 2Cases of chronic infectionPatientDuration of infectionYear of acquisitionEradication attemptedEradication successfulOutcome1 (O'Carroll, 2003) \[[@CR12]\]\>15 years1987NoN/ASlow decline in lung health consistent with CF; transplant 200410 (O'Carroll, 2003) \[[@CR12]\]11 years2001NoN/ASlow decline in lung health consistent with CF3 (Schülin, 2001) \[[@CR14]\]\>9 years1992YesNoIncreased frequency of exacerbations15\>8 years2005YesNoAccelerated decline; transplant declined due to *B. pseudomallei* infection; *B. pseudomallei* septicaemia;^a^ died 200922 (Radhakrishna, 2014) \[[@CR17]\]7 years2011YesYesNo obvious clinical impact27 yearsEarly 1990'sNoN/ASpontaneously clearance of infection after approx. 7 years; 11 years later died of neutropenic sepsis complicating treatment of Duke's C colon cancer.7 (Holland, 2002) \[[@CR16]\]\>6 years2000YesNoAccelerated decline with increased frequency of exacerbations; *B. pseudomallei* septicaemia; died 2009176 years2007NoN/ASlow decline in lung health consistent with CF186 years2007YesNoAccelerated decline; transplant declined due to *B. pseudomallei*; died 201311 (Holland, 2002) \[[@CR15]\]5 years2001YesNoAccelerated decline; transplant 2006; died 201123\>12 months2012YesNoProgressive destruction right upper lobe6 (Holland, 2002) \[[@CR16]\]\>4 years1999YesNoAfter presumed latency of 4 years developed accelerated decline with pneumonia; died 2004244 years2009YesUnknownFall in lung function; stable after targeted antimicrobial therapy14 (Barth, 2007) \[[@CR9]\]\>2 years2005YesNoAccelerated decline with rapid decrease in lung function and recurrent exacerbations over 2 years; long term outcome unknown8 (O'Carroll, 2003) \[[@CR12]\]2 years2000YesNoRapid decline post infection; died 2 years after initial infection212 years2010YesNoAccelerated decline; transplant 2012 with persistent infection post-transplant12 (O'Carroll, 2003) \[[@CR12]\]2 years2001YesYesRepeated admissions with pneumonia, treated with 3 week courses of ceftazidime, meropenem, tobramycin; infection ultimately spontaneously cleared4 (Visca, 2001) \[[@CR15]\]1 year1998YesYesDeteriorating pulmonary sepsis, increasingly refractory to anti-pseudomonal antibiotics; cleared infection with antimicrobial therapy; still alive 201313 (Asiah, 2006) \[[@CR8]\]1 year2004YesYesIncreased pulmonary sepsis during infection with *B. pseudomallei*; remained well 5 months after completing targeted anti-microbial therapy^a^Recurrent episodes of *B. pseudomallei* bacteremia^b^In patient 5 the duration of infection and long term outcome was unknown

In five patients, evidence of chronic infection (duration 5--17 years) was not associated with clinical deterioration (patients 1, 2, 10, 17 and 22).

In one patient duration of infection and outcome was unknown (patient 5), and another one patient was identified shortly prior to publication (patient 25). Initial sputa have been clear after three weeks of intravenous antibiotics. The patient continues on suppressive oral antibiotics, and long term outcomes are awaited.

Eradication strategies {#Sec8}
----------------------

Specific eradication strategies were documented in 19 of the 25 patients. Six patients (including patient 9 - multiple episodes of infection) achieved clearance of *B. pseudomallei*. Eradication attempts were unsuccessful in 11 patients and there was an unknown outcome in two patients (patient 24, patient 25, Table [3](#Tab3){ref-type="table"}). For cases of successful eradication, the period of known infection was usually less than 12 months, whereas failed eradication usually occurred where long-term infection was evident. Ceftazidime was a key component of induction therapy in all but one of the patients with successful eradication, and all had consolidation therapy from one to four months after completion of intravenous antibiotics and in most cases, oral TMP/SMX was used. In select cases, antibiotic regimens also included combinations of oral amoxicillin/clavulanic acid, doxycycline and chloramphenicol, and nebulized meropenem (250--500 mg twice daily in 4 ml of sterile water).Table 3Eradication strategiesPatientDuration of infection prior to treatmentInductionConsolidationTreatmentDurationTreatmentDurationSuccessful eradication16 (Corral, 2008) \[[@CR10]\]Unknown -- lived in BVIMeropenem 2 g tds19 daysTMP/SMX 960 mg bd19 daysMinocycline 100 mg bdMinocycline 100 mg bdTobramycin (neb)^a^ 80 mg bd20 (O'Sullivan, 2011) \[[@CR13]\]3 monthsImipenem14 daysMeropenem (neb)28 daysCeftazidimeTMP/SMX 960 mg bd2 years4 (Visca, 2001) \[[@CR15]\]12 monthsCeftazidime42 daysTMP/SMX 960 mg bd210 daysTMP/SMX 960 mg bdDoxycyclineChloramphenicol13 (Asiah, 2006) \[[@CR8]\]12 monthsCeftazidime56 daysTMP/SMX 960 mg bd112 daysTMP/SMX 960 mg bdDoxycycline22 (Radhakrishna, 2014) \[[@CR17]\]7 yearsMeropenem 2 g tdsApprox 56 daysDoxycycline followed by amoxycillin/clavulanic acid (doxycycline allergy)12 monthsCeftazidime 3 g tdsTobramycin (neb) 80 mg bdTMP/SMX 960 mg bd9 (Holland, 2002) \[[@CR16]\] Infection 1UnknownCeftazidime14 daysTMP/SMX 960 mg bd90 daysTMP/SMX 960 mg bd9 (Holland, 2002) \[[@CR16]\] Infection 21 monthCeftazidime21 daysTMP/SMX 960 mg bd90 daysTMP/SMX 960 mg bd9 (Holland, 2002) \[[@CR16]\] Infection 31-2 monthsCeftazidime14 daysTMP/SMX 960 mg bd90 daysTMP/SMX 960 mg bdFailed Eradication8 (O'Carroll, 2003) \[[@CR12]\]4 monthsMeropenem 2 g tds56 daysNoneCeftazidime 3 g tds176-12 monthsCeftazidime 3 g tds14 daysTMP/SMX 960 mg bd84 daysTMP/SMX 960 mg bd23\>10 monthsCeftazidime 3 g tds21 daysUnknown (patient moved to Malaysia)TMP/SMX 960 mg bdTobramycin 5 mg/kg3 (Schülin, 2001) \[[@CR14]\]6 yearsUnspecified antipseudomonal antibiotics14 daysNo (exacerbations directed against PsA)14 (Barth, 2007) \[[@CR9]\]\>18 monthsPipracillin/clavulanate21 daysMeropenem 2 g tds21 daysTobramycin 5 mg/kgCeftazidime 3 g tdsAmikacinTMP/SMX 960 mg bd15\>8 yearsMeropenem 2 g tds14 daysTMP/SMX 960 mg bd126 daysTobramycinMinocycline 100 mg bdMeropenem (neb)18 (1^st^ attempt)2 monthsCeftazidime 1.5 g tds14 daysInfection not cleared therefore 2^nd^ course of IV antibioticsTobramycin 300 mgAmoxycillin/Clavulanic acid 900 mg18 (2^nd^ attempt)2 monthsMeropenem84 daysTMP/SMX 960 mg bdLong termCeftazidimeDoxycyclineAmoxycillin/Clavulanic acid6 (Holland, 2002) \[[@CR16]\]\>4 yearsCeftazidime 50 mg/kg120 daysNone (exacerbations directed against *B. pseudomallei*)Piperacillin 50 mg/kgAmoxycillin/Clavulanic acid7 (Holland, 2002) \[[@CR16]\]\>5 yearsTMP/SMX 960 mg bd4 years1^st^ isolation7 (Holland, 2002) \[[@CR16]\]\>9 yearsImipenem20 daysTMP/SMX 960 mg bd19 days2^nd^ isolationPiperacillin/Clavulanic acid42 daysTetracycline30 daysMeropenem/TMP/SMX\>30 days11 (Holland, 2002) \[[@CR16]\]3 monthsCeftazidime14 daysTMP/SMX 960 mg bd330 daysTobramycin211 monthMeropenem 2 g tds42 daysTobramycin (neb) 300 mg bd42 daysCeftazidime 3 g tdsTMP/SMX 960 mg bdTobramycin 7 mg/kgSuccess of eradication for patient 24 and patient 25 unknown^a^neb = nebulized

Two patients spontaneously cleared infection without specific eradication strategies (patients 2 and 19) (Table [2](#Tab2){ref-type="table"}). Whilst not a formal approach at eradication of *B. pseudomallei*, patient 12 was treated with 3-week courses of ceftazidime, meropenem and tobramycin over a 15-month period for repeated episodes of pneumonia, after which time *B. pseudomallei* was no longer cultured from sputum.

Transplantation with *B. pseudomallei* {#Sec9}
--------------------------------------

Transplantation was considered for six patients but two patients were not listed due to concerns about the potential risk of *B. pseudomallei* graft infection after transplantation (patient 15, patient 18). One patient was listed for transplant but deteriorated very rapidly and died several months later without transplant (patient 8). Three patients have undergone lung transplants (patients 1, 11 and 21) and immediate post-transplant results have been satisfactory. One patient (patient 1) remains well 10 years post-transplant with normal lung function despite endobronchial washings remaining positive for *B. pseudomallei*; another patient (patient 12) died five years after transplantation, and post-transplant endobronchial washings were positive; and the third patient (patient 21) is alive two years after transplantation also with *B. pseudomallei* recurrently isolated from post-transplant respiratory samples. Chronic *B. pseudomallei* suppression has been used in all cases (either TMP/SMX or doxycycline).

Discussion {#Sec10}
==========

CF is a disease that predominates in people of Caucasian descent and most patients do not live in tropical or sub-tropical regions where *B. pseudomallei* is endemic. As survival has increased, CF patients have increasingly had the opportunity to travel, and as a consequence over the past two decades there have been a number of reports of infection with *B. pseudomallei* in CF patients \[[@CR8]--[@CR17]\].

We have identified 25 cases of *B. pseudomallei* in CF patients and the vast majority of CF patients who have become infected with *B. pseudomallei* have acquired the organism through travel to endemic areas such as Southeast Asia and northern Australia. Most patients already had significant structural lung disease and low BMI, which suggests these factors are likely to be important risk factors for acquisition of the organism in CF. However severe CF disease *per se* was not an obvious prerequisite for acquisition. Some patients were also diabetic but other risk factors for melioidosis such as hazardous alcohol use, chronic renal disease, heart disease and immunosuppressive therapy were not present in this cohort.

In contrast with the general population, acquisition of *B. pseudomallei* in CF appeared to be more likely to result in chronic infection, which is problematic given how difficult it can be to eradicate this pathogen even with targeted antimicrobial therapy. Whilst the clinical manifestations of infection were varied in the CF patients, and a chronic quiescent disease state can obviously occur, the establishment of chronic infection in most patients usually heralded further clinical deterioration, with progressively refractory bronchopulmonary sepsis being a common feature. Delayed diagnosis may contribute to chronic infection and early attempts to eradicate are recommended. This requires expeditious recognition of the infection in travellers returning from endemic areas. The identification of *B. pseudomallei* can be challenging, and it is possible that isolates may be confused with other more common CF pathogens including other Burkholderia species, particularly if laboratories are not familiar with *in vitro* characteristics of *B. pseudomallei* \[[@CR8], [@CR14], [@CR15]\]. Furthermore, infection with *B. pseudomallei* does not always result in immediate onset of symptoms as it often would in patients without CF, and symptoms may masquerade as those typical of pulmonary exacerbation. It is therefore important that CF clinicians have a high index of suspicion for patients returning from endemic areas.

Whilst not universally successful, approaches that utilise a 2--3 week course of parenteral ceftazidime, followed by a 3-month consolidation course of oral.

TMP/SMX, appear to be the most effective. This approach is similar to that recommended for melioidosis therapy \[[@CR1], [@CR2], [@CR19]\]. If initial response does not successfully result in persistently negative sputum cultures for *B. pseudomallei,* then a longer course of parenteral ceftazidime or meropenem (≥4 weeks) should be considered \[[@CR2]\]. If patients are allergic to or intolerant of TMP/SMX, consolidation with several months of doxycycline or amoxycillin/clavulanic acid have also been successfully used. When eradication is not possible, and a progressive decline in health ensues, lung transplantation may be considered. To date, early post-transplant outcomes have been acceptable despite persistence of *B. pseudomallei*.

This case series has several limitations. Firstly, it is likely other cases have not been identified, either because they have not been reported, or the infection was not recognised. For example, we excluded three possible cases from Mexico because of insufficient details \[[@CR18]\]. Secondly, outcomes were not available for some patients, we were unable to access data (patients 5, 13 and 14), or cases lost to follow-up (patients 16 and 23). Interestingly, two patients were reported by two CF centres, by two UK-based centres, and by centres in the UK and Canada, respectively (patients 15 and 16). After further investigation we noted they were the same persons, highlighting the mobility of CF patients.

Conclusion {#Sec11}
==========

The international experience with *B. pseudomallei* described here demonstrates that this organism has the potential to exhibit novel behaviours in the CF host, including the development of chronic infection. Further analysis of *B. pseudomallei* isolates from those CF patients with persisting infection may inform on the key mechanisms contributing to bacterial persistence \[[@CR7]\]. As a result of this analysis suggest the following recommendations:Clinicians should have a high index of suspicion for *B. pseudomallei* infection for CF patients living in or returning from areas where it is endemic. Suspicion should be heightened when fever and or pneumonia occurs. Close liaison with the CF microbiology laboratory is important.Eradication of *B. pseudomallei* infection should be attempted for CF patients when this pathogen is first isolated.Initial intravenous therapy should include a minimum of two weeks intravenous ceftazidime (and or meropenem if severe sepsis). Consideration should be given to extending the duration of intravenous in those CF patients who are persistently culture-positive on therapy. We also recommend addition of oral/intravenous TMP/SMX from the onset of therapy and this should continue where possible for three months, with regular clinical monitoring for potential adverse effects including renal and hepatic dysfuntion, bone marrow toxicity and potentially life-threatening skin reactions including DRESS syndrome (drug reaction with eosinophilia and systemic symptoms).Travel should be avoided to northern Australia or south-east Asia during the monsoonal season, with particular care to minimise exposure to wet season soils and rain in resident patients \[[@CR20]\].Person-to-person transmission of *B. pseudomallei* is generally thought not to occur. However one case of siblings who developed infection with identical strains raises the possibility of cross-infection in CF and should carefully consider the risks and benefits of segregation of patients who have isolated this organism.

Additional files {#Sec12}
================
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BMI

:   Body mass index

*B. pseudomallei*

:   *Burkholderia pseudomallei*

CF

:   Cystic fibrosis

CFTR

:   Cystic Fibrosis Transmembrane Conductance Regulator

FEV1

:   Forced expiratory volume in 1 second

TMP/SMX

:   Trimethoprim/sulfamethoxazole
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Summary At A Glance: We confirmed that *Burkholderia pseudomallei* commonly behaves in novel ways in the CF host, frequently establishing chronic infection, which often results in poor long-term outcomes. Eradication should be attempted early where possible, but if unsuccessful, transplantation can be carefully considered despite chronic infection.
